Diagnostic algorithm for metabolic myopathies

Current Neurology and Neuroscience Reports

Volumn 10, Issue 2, 2010, Pages 118-126

  Berardo, Andres ^a   DiMauro, Salvatore ^a   Hirano, Michio ^a  

^a New York Presbyterian Morgan Stanley Children's Hospital   (United States)

Author keywords

Fatty acid; Glycogenosis; Metabolic myopathies; Mitochondrial diseases

Indexed keywords

ALGORITHM; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DISORDERS OF MITOCHONDRIAL FUNCTIONS; GLYCOGEN STORAGE DISEASE; MELAS SYNDROME; MYOPATHY; REVIEW;

ALGORITHMS; GLYCOGEN; HUMANS; LIPID METABOLISM DISORDERS; METABOLIC NETWORKS AND PATHWAYS; METABOLISM, INBORN ERRORS; MITOCHONDRIAL DISEASES; MODELS, BIOLOGICAL; MUSCULAR DISEASES;

EID: 77953545301     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-010-0096-4     Document Type: Review

References (53)

1. Darras BT, Friedman NR: Metabolic myopathies: A clinical approach: Part I. Pediatr Neurol 2000, 22:87-97.
2. van Adel BA, Tarnopolsky MA: Metabolic myopathies: Update 2009. J Clin Neuromuscul Dis 2009, 10:97-121. This article reviews the key clinical features, diagnostic tests, and treatment recommendations for the more common metabolic myopathies.
3. DiMauro S, Lamperti C: Muscle glycogenoses. Muscle Nerve 2001, 24:984-999.
4. Tein I: Neonatal metabolic myopathies. Semin Perinatol 1999, 23:125-151.
5. Eymard B, Laforět P: Metabolic myopathies in adulthood. Features and clues for diagnosis [in French]. Rev Med Interne 2001, 22:328-337.
6. Spiegel R, Gomez EA, Akman HO, et al.: Myopathic form of phosphoglycerate kinase (PGK) deficiency: A new case and pathogenic considerations. Neuromuscul Disord 2009, 19:207-211.
7. Stojkovic T, Vissing J, Petit F, et al.: Muscle glycogenosis due to phosphoglucomutase 1 deficiency. N Engl JMed 2009, 23:425-427.
8. Haller RG: Treatment of McArdle disease. Arch Neurol 2000, 57:923-924.
9. Haller RG, Vissing J: Spontaneous 'second wind' and glucoseinduced second 'second wind' in McArdle disease: Oxidative mechanisms. Arch Neurol 2002, 59:1395-1402.
10. Taivassalo T, Jensen TD, Kennaway N, et al.: The spectrum of exercise tolerance in mitochondrial myopathies: A study of 40 patients. Brain 2003, 126:413-423.
11. ørngreen MC, Schelhaas HJ, Jeppesen TD, et al.: Is muscle glycogenolysis impaired in X-linked phosphorylase b kinase deficiency? Neurology 2008, 70:1876-1882.
12. Deschauer M Wieser T, Zierz S: Muscle carnitine palmitoyltransferase II deficiency: Clinical and molecular genetic features and diagnostic aspects. Arch Neurol 2005, 62:37-41
13. ørngreen MC, Dunø M, Ejstrup R, et al.: Fuel utilization in subjects with carnitine palmitoyl-transferase 2 gene mutations. Ann Neurol 2005, 57:60-66.
14. Haller RG, Vissing J: No spontaneous second wind in muscle phosphofructokinase deficiency. Neurology 2004, 62:82-86.
15. Vissing J, Haller RG: The effect of oral sucrose on exercise tolerance in patients with McArdle's disease. N Engl J Med 2003, 349:2503-2509.
16. Vissing J, Quistorff B, Haller RG: Effect of fuels on exercise capacity in muscle phosphoglycerate mutase deficiency. Arch Neurol 2005, 62:1440-1443.
17. Toscano A, Musumeci O: Tarui disease and distal glycogenoses: Clinical and genetic update. Acta Myol 2007, 26:105-107.
18. Beutler E: PGK deficiency. Br J Haematol 2007, 136:3-11.
19. Tsujino S, Nonaka I, DiMauro S: Glycogen storage myopathies. Neurol Clin 2000, 18:125-150.
20. Regelsberger G, Höftberger R, Pickl WF, et al.: Danon disease: Case report and detection of new mutation. J Inherit Metab Dis 2009 Jul 7 (Epub ahead of print).
21. Klein CJ, Boes CJ, Chapin JE, et al.: Adult polyglucosan body disease: Case description of an expanding genetic and clinical syndrome. Muscle Nerve 2004, 29:323-328.
22. Noel N, Flanagan JM, Ramirez Bajo MJ, et al.: Two new phosphoglycerate kinase mutations associated with chronic haemolytic anaemia and neurological dysfunction in two patients from Spain. J Haematol 2006, 132:523-529.
23. Shen J, Bao Y, Liu HM, et al.: Mutations in exon 3 of the glycogen debranching enzyme gene are associated with glycogen storage disease type III that is differentially expressed in liver and muscle. J Clin Invest 1996, 98:352-357.
24. Longo N, Amat di San Filippo C, Pasquali M: Disorders of carnitine transport and the carnitine cycle. Am J Med Genet C Semin Med Genet 2006, 142:77-85.
25. Bruno C, DiMauro S: Lipid storage myopathies. Curr Opin Neurol 2008, 21:601-606. This article provides an excellent update on lipid storage myopathies.
26. DiMauro S, DiMauro PM: Muscle carnitine palmityltransferase deficiency and myoglobinuria. Science 1973, 182:929-931.
27. Hamano H, Shinohara Y, Takizawa S, et al.: Very-long-chain acyl- CoA dehydrogenase deficiency presenting with recurrent rhabdomyolysis in an adult. Rinsho Shinkeigaku 2003, 43:253-257.
28. Curcoy A, Olsen RK, Ribes A, et al.: Late-onset form of betaelectron transfer flavoprotein deficiency. Mol Genet Metab 2003, 78:247-249.
29. Horvath R, Schneiderat P, Schoser BG, et al.: Coenzyme Q10 deficiency and isolated myopathy. Neurology 2006, 66:253-255.
30. Gempel K, Topaloglu H, Talim B, et al.: The myopathic form of coenzyme Q10 deficiency is caused by mutations in the electrontransferring- flavoprotein dehydrogenase (ETFDH) gene. Brain 2007, 130:2037-2044. This is the first documentation of ETFdehydrogenase mutation riboflavin-responsive MADD, indicating that this disorder and the myopathic form of CoQ10 deficiency may be allelic diseases.
31. Elston T, Wang H, Oster G: Energy transduction in ATP synthase. Nature 1998, 391:510-513.
32. Noji H, Yoshida M: The rotary machine of the cell, ATP synthase. J Biol Chem 2001, 276:1665-1668. (Pubitemid 32109632)
33. DiMauro S, Schon E: Mitochondrial disorders in the nervous system. Ann Rev Neurosci 2008, 31:91-123. This is an excellent, comprehensive review of mitochondrial diseases.
34. Suomalainen A, Kaukonen J: Diseases caused by nuclear genes affecting mtDNA stability. Am J Med Genet 2001, 106:53-61.
35. Spinazzola A, Zeviani M: Disorders of nuclear-mitochondrial intergenomic signaling. Biosci Rep 2007, 27:39-51.
36. Zhu X, Peng X, Guan MX, et al.: Pathogenic mutations of nuclear genes associated with mitochondrial disorders. Acta Biochim Biophys Sin (Shanghai) 2009, 41:179-187.
37. Rowland LP, Blake DM, Hirano M, et al.: Clinical syndromes associated with ragged red fibers. Rev Neurol 1991, 147:467-473.
38. Zeviani M, Moraes CT, DiMauro S, et al.: Deletions of mitochondrial DNA in Kearns-Sayre syndrome. Neurology 1998, 51:1525-1533.
39. Sproule DM, Kaufmann P: Mitochondrial encephalopathy, lactic acidosis, and strokelike episodes: Basic concepts, clinical phenotype, and therapeutic management of MELAS syndrome. Ann N Y Acad Sci 2008, 1142:133-158.
40. Goto Y, Nonaka I, Horai S: A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature 1990, 348:651-653.
41. Mehrazin M, Shanske S, Kaufmann P, et al.: Longitudinal changes of mtDNA A3243G mutation load and level of functioning in MELAS. Am J Med Genet A 2009, 149:584-587.
42. McDonnell MT, Schaefer AM, Blakely EL: Noninvasive diagnosis of the 3243A> mitochondrial DNA mutation using urinary epithelial cells. Eur J Hum Genet 2004, 12:778-781.
43. Shanske S: Varying loads of the mitochondrial DNA A3243G mutation in different tissues: Implications for diagnosis. Am J Med Genet 2004, 130:134-137.
44. Marotta R, Reardon K, McKelvie PA, et al.: Association of the MELAS m.3243A> mutation with myositis and the superiority of urine over muscle, blood and hair for mutation detection. J Clin Neurosci 2009, 16:1223-1225.
45. Wiedemann FR, Bartels C, Kirches E, et al.: Unusual presentations of patients with the mitochondrial MERRF mutation A8344G. Clin Neurol Neurosurg 2008, 110:859-863.
46. Melone MA, Tessa A, Petrini S, et al.: Revelation of a new mitochondrial DNA mutation (G12147A) in a MELAS/MERFF phenotype. Arch Neurol 2004, 61:269-272.
47. Andreu AL, Hanna MG, Reichmann H, et al.: Exercise intolerance due to mutations in the cytochrome b gene of mitochondrial DNA. N Engl J Med 1999, 341:1037-1044.
48. Bortot B, Barbi E, Biffi S,et al.: Two novel cosegregating mutations in tRNAMet and COX III, in a patient with exercise intolerance and autoimmune polyendocrinopathy. Mitochondrion 2009, 9:123-129.
49. Pulkes T, Liolitsa D, Wills AJ, et al.: Nonsense mutations in mitochondrial DNA associated with myalgia and exercise intolerance. Neurology 2005, 64:1091-1092.
50. Andreu AL, Tanji K, Bruno C, et al.: Exercise intolerance due to a nonsense mutation in the mtDNA ND4 gene. Ann Neurol 1999, 45:820-823. (Pubitemid 29260765)
51. Downham E, Winterthun S, Nakkestad HL, et al.: A novel mitochondrial ND5 (MTND5) gene mutation giving isolated exercise intolerance. Neuromusc Disord 2008, 18:310-314.
52. McFarland R, Taylor RW, Chinnery PF, et al.: A novel sporadic mutation in cytochrome c oxidase subunit II as a cause of rhabdomyolysis. Neuromusc Disord 2004, 14:162-166.
53. Hirano M: Metabolic myopathies. In Neurobiology of Disease. Edited by Gilman S. San Diego, CA: Elsevier Academic Press; 2007:947-956.